Mergers & Acquisitions

New York –- Walgreens has reportedly filed for an eight-part benchmark bond offering to help finance its planned $5.3 billion purchase of U.K. drugstore retailer Alliance Boots GmBH. According to Bloomberg, Walgreens has filed with the SEC for three-, five-, seven-, 10-, 20- and 30-year fixed-rate bonds, as well as 18-month and three-year floating-rate notes.  

By Don Cardon and Steve Backman         

Former Maidenform CEO Maurice Reznic was named Delta Galil’s CEO of women’s intimate apparel for U.S. and U.K. and president of its U.S. branch.

Louisville, Ky. -- Mid-America Real Estate Corporation’s Investment Sales team recently brokered the sale of Stonefield Square in Louisville, Ky. The 90,991-sq.-ft. center was purchased from seller Viking Partners by Toronto-based Slate Properties for $12.6 million.   Stonefield Square is located at the southwest corner of Shelbyville and Moser Roads. The center is anchored by The Fresh Market, CVS and Fifth Third Bank.

Boston -- Charter Realty & Development Corp. announced the acquisition of 60-70 Cross Street in Boston’s North End. The property is the latest addition to Charter’s growing commercial portfolio in Massachusetts and kick-starts its new urban program. Charter currently owns and operates over a million and a half square feet of commercial space in the Bay State.  

Leading third party logistics provider Transplace acquired fellow 3PL Logistics Management Solutions in a deal that extends the company’s expertise to chemical and industrial manufacturing.

General Mills has elected David M. Cordani to its board of directors.  Cordani, 48, is a president and CEO of Cigna Corporation, a global health insurance and health services company.  

Cordani joined Cigna in 1991 and has held a variety of finance and operating positions, including CEO for CIGNA Healthcare and president and CEO for Cigna Corporation.  

Woonsocket, R.I. -- CVS Health Corp. on Tuesday reported slightly higher-than-expected quarterly profit, helped in part by growth in sales of specialty drugs. Net income decreased 24% to $900 million from $1.21 billion in the year-ago period, primarily due to a $521 million pre-tax loss on the early extinguishment of debt.